NeuroPace, Inc. (NPCE)
| Previous close | 7.98 |
| Open | 7.91 |
| Bid | 8.02 x 100 |
| Ask | 8.20 x 100 |
| Day's range | 7.69 - 8.10 |
| 52-week range | 3.80 - 18.15 |
| Volume | |
| Avg. volume | 121,274 |
| Market cap | 231.871M |
| Beta (5Y monthly) | 2.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.27 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.25 |
GlobeNewswireNeuroPace to Participate in Two Healthcare Conferences in May
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in May. NeuroPace management will participate in the Wells Fargo 2024 West Coast MedTech Tour at 2:30pm PT on Tuesday, May 28 in Menlo Park, CA. The format will be a fireside chat with a group of investors. NeuroPace will also present at the Leerink Partn
Insider MonkeyNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript May 12, 2024 NeuroPace, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to NeuroPace’s First Quarter 2024 Conference Call. As a reminder, this call is being recorded. […]
- GuruFocus.com
NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges
Comprehensive Analysis of NeuroPace's Fiscal Performance and Strategic Updates
